

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- In the Phase III CLL14 trial, which regimen was more efficacious than chlorambucil with obinutuzumab for patients with previously untreated CLL?**
  - Venetoclax with Obinutuzumab**
  - Ibrutinib with Obinutuzumab
  - Acalabrutinib with Obinutuzumab
  - Zanubrutinib with Obinutuzumab
- Which of the following studies reported a treatment benefit with the next-generation BTK inhibitor, Zanubrutinib?**
  - GLOW
  - ALPINE**
  - CLL14
  - ELEVATE-TN
- Which of the following combinations was evaluated as first-line therapy for patients with CLL in the phase III GLOW trial?**
  - Ibrutinib with Venetoclax**
  - Acalabrutinib with Venetoclax
  - Zanubrutinib with Venetoclax
  - Obinutuzumab with Venetoclax
- The phase III study comparing Ibrutinib + Venetoclax versus Chlorambucil + Obinutuzumab in patients with previously untreated CLL/SLL revealed a decrease in which adverse event in the Ibrutinib/Venetoclax arm?**
  - Infections
  - Diarrhea
  - Tumor Lysis Syndrome**
  - Atrial fibrillation